The Effect of MediYoga on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fibrillation: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Atrial fibrillation (AF) is the most common cardiac arrythmia, associated with increased risk of stroke, heart failure, reduced quality of life (QoL), and psychological distress. This randomized controlled trial investigates the effect of MediYoga - a program incorporating deep breathing, low-intensity yoga, and meditation- on disease-specific QoL, blood pressure, and heart rate in 456 patients with paroxysmal AF. With a strong focus on sustainability, the study is fully digital: participants are recruited online, and the 12-week intervention is delivered through an application to smartphone. Additionally, the participants receive online support via Teams. Data will be collected at baseline, 3, 6, and 12 months. The primary outcome is disease specific QoL; secondary outcomes include blood pressure, heart rate, generic QoL, and psychological wellbeing. Qualitative interviews will explore patients' experiences with the intervention.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Aged 18 and above

• Diagnosed with paroxysmal atrial fibrillation

• EHRA score at 2 or more

• Owner of a smartphone or tablet

• Speaking and reading Danish

• No comorbidity that restricts them from participating in the intervention

Locations
Other Locations
Denmark
Herlev and Gentofte University Hospital
RECRUITING
Herlev
Contact Information
Primary
Signe S Risom, Associated Professor
signe.stelling.risom@regionh.dk
+45 5163 2786
Backup
Camilla H Johansen, Msc
signe.stelling.risom@regionh.dk
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 456
Treatments
Experimental: Intervention Group I, yoga 20 minutes x3 pr week
Experimental: Intervention group II, yoga 60 minutes x1 pr week
No_intervention: Control group
Treatment as usual
Sponsors
Collaborators: Sophiahemmet
Leads: Herlev and Gentofte Hospital

This content was sourced from clinicaltrials.gov